480 results about "Glioma" patented technology

The present invention discloses substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8H-purin-8-one compounds compounds having the structural formula represented by formula (I)： The substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8H-purin-8-one compounds, derivatives and pharmaceutically acceptable salts thereof of the present invention are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a DNA-dependent protein kinase (DNA-PK) and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, glioma, glioblastoma, DIPG, and the like either as monotherapy or combination with other treatments, such as radiation therapy or chemotherapy.

The invention relates to the technical field of boundary recognition, in particular to a glioma boundary recognition method and system based on image fusion, and the method comprises the following steps: obtaining a multi-modal brain image, constructing a fusion matrix, extracting the gray features of an edge region and an adjacent region, recognizing signal-noise abnormal points, and revising a judgment standard. And adjusting the path direction and reconstructing an edge communication structure, and generating a glioma boundary region map under fusion. According to the method, high-precision alignment among modals is realized through multi-modal image gray scale unification and registration processing, key details are expanded and focused by enhancing edges and regions, the recognition accuracy is improved, gray scale comparison between the edges and outer adjacent regions is introduced, the signal distinguishing capability is enhanced, misjudgment is avoided, judgment conditions are dynamically revised according to the signal-noise difference, and the accuracy of recognition is improved. The method enables the recognition standard to have local adaptability, combines the path change trend to reorder and connect edge points, guarantees the continuity of a boundary structure, integrally improves the accuracy and integrity of fuzzy boundary recognition, and enhances the glioma contour extraction effect.

The invention discloses a tryptamine compound as well as a preparation method and application thereof. The tryptamine compound can be used for preparing medicines for preventing and / or treating cancers. The cancer is at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on a plurality of compounds, the three tryptamine compounds provided by the invention are found to have excellent inhibitory activity on a plurality of different types of human cancer cells for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention discloses sesquiterpenoids as well as a preparation method and application thereof. The structure of the sesquiterpenoids is shown in the specification. The sesquiterpenoids of # imgabs0 can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, kidney cancer and skin cancer. According to the invention, various natural product extracts are subjected to activity screening, the sesquiterpenoids derived from the rattan chrysanthemum have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low.

The invention discloses a tumor space-occupying brain network neural image alignment method based on multi-modal fusion, and belongs to the technical field of medical image processing and artificial intelligence crossing. The method comprises the following core steps of multi-modal image heterogeneous feature decoupling, tumor occupation deformation field modeling, functional network topological structure maintenance, cross-modal feature adversarial alignment, dynamic deformation constraint optimization and clinical interpretability verification, and construction of a three-dimensional non-rigid registration network based on a double attention mechanism. And differential homeomorphic mapping of a tumor focus area and normal brain tissue is realized through the cascaded spatial transformation module. Aiming at the problems of insufficient multi-modal feature alignment and brain network topology distortion in the prior art, the invention provides a function connection constrained cross-modal fusion strategy, a graph convolution network is adopted to encode resting state function connection features, and network node displacement caused by tumor occupation is dynamically corrected in combination with deformable convolution and a bidirectional feature competition mechanism; a space consistency loss function based on white matter fiber bundle tracing is designed, and through diffusion tensor imaging feature guide structure-function bimodal joint optimization, the problems of insufficient registration precision in a focus area and whole brain network connection distortion of a traditional method are solved. Experiments show that the registration precision of the method in glioma cases reaches 0.82 mm and is improved by 37% compared with that of a traditional method, and dissection-function consistency of functional network reconstruction around tumors is remarkably improved.

The invention provides a SegTCLIP glioma segmentation method and system based on data amplification and a semantic map and application, and relates to the technical field of medical image processing and image segmentation, the method comprises the following steps: pre-processing a glioma image collected in advance, and carrying out missing mode filling processing on the pre-processed glioma image; performing feature extraction on the glioma image after filling processing and the corresponding text data, mapping the features into embedded vectors, and constructing an image-text mixed feature map; and calculating a pixel-text score graph based on the multi-modal pixel feature graph, and inputting the image-text mixed feature graph and the pixel-text score graph into a multi-modal decoding network for feature decoding to obtain a segmentation result. According to the method, the problems of glioma image modal deficiency and insufficient glioma image and text information fusion are solved, and meanwhile, the accuracy of complex glioma region segmentation is improved.

The invention relates to the technical field of image analysis, in particular to a multi-modal data fusion IDH wild type glioblastoma typing method and system, and the method comprises the steps: obtaining a data set of a GBM patient; based on the data set, radiomics characteristics, pathomics characteristics, whole exon sequencing data, transcriptome sequencing data and proteomics characteristics are obtained; performing multi-modal data fusion on the image omics characteristics, the pathological omics characteristics, the whole exon sequencing data, the transcriptome sequencing data and the proteomics characteristics, and constructing a multi-modal fusion typing framework to identify the MOFS subtype; and based on image omics features, constructing a deep neural network classifier for predicting the MOFS subtype, and verifying the identified MOFS subtype. Three different subtypes in IDH wild-type adult glioma are determined and verified using an artificial intelligence method by integrating multi-mode data from MRI derived radiomics, WSI derived pathomics, WES, RNA sequencing, and MS-based proteomics.

The invention relates to the technical field of radiotherapy dose prediction, in particular to a glioma radiation dose prediction system based on an attention-enhanced convolutional neural network, which comprises a data collection module, a data preprocessing module, a convolutional neural network module, an attention mechanism module and an output layer. According to the invention, by introducing the attention mechanism, the important feature region can be effectively highlighted, so that the prediction accuracy of the radiation dose of the glioma patient is improved, and the individuation and precision of the treatment scheme are ensured; a dose distribution result can be quickly generated through automatic dose prediction, time and energy investment of doctors in radiotherapy plan design is reduced, working efficiency is improved, accuracy and efficiency of glioma radiotherapy are remarkably improved, clinical decisions are optimized, medical cost is reduced, and support is provided for intelligentization and automation of radiotherapy. Through the research of the project, the application of the deep learning technology in the field of medical image analysis is promoted, and the overall level of radiotherapy is improved.

The invention provides a drug screening and curative effect evaluation method and system based on a glioma organ-like model, and relates to the technical field of biological material analys.The method includes the steps that a three-dimensional fluorescence image of the glioma organ-like model is collected, signal intensity analysis and compensation processing are carried out, a growth feature mapping model is constructed, and the three-dimensional fluorescence image of the glioma organ-like model is obtained; and phenotypic characteristics for representing the glioma organoid heterogeneity are obtained. Inputting the phenotypic characteristics into a drug response evaluation network, and calculating a drug sensitivity score; the drug molecular feature library and the drug collaborative analysis model are combined, the synergistic interaction index of different drug combinations is calculated, the optimal drug combination is screened, the drug administration dosage and the drug administration time sequence are determined in combination with phenotypic features, and finally an individualized treatment scheme is generated. According to the invention, the curative effect of the drug on the glioma organs can be effectively evaluated, and the optimal drug combination and administration scheme can be screened out, so that the accuracy and effectiveness of glioma treatment are improved.

The invention relates to a glioma radiotherapy effect prediction method based on habitat analysis imageomics, and belongs to the technical field of medical image artificial intelligence and tumor radiotherapy, and the method comprises the steps: collecting a multi-mode MRI image, a radiotherapy plan computed tomography CT image, a dose image and a local recurrence label before postoperative radiotherapy, and converting the images into a standard format; sequentially performing craniocerebral boning processing, N4 bias field correction, isotropic resampling, gray level normalization processing and image registration on the acquired image to obtain a preprocessed image; based on the planned target volume PTV, dividing the interior of the PTV into three types of physiological structure habitat areas and three types of physiological habitat areas; image omics features of the multi-mode MRI images are extracted in the PTV and all habitat areas, and an optimal feature subset is screened out; taking the screened optimal feature subset as an input, taking the local recurrence label as an output label, and selecting an optimal model; and generating an output result by using the optimal model.

The invention relates to the related technical field of primary cell (PDC) culture, in particular to a method for culturing primary cells (PDC) from glioma patients, which comprises a series of steps of Swis3T3-J2 cell culture, conditioned medium preparation, brain tumor tissue pretreatment, primary tumor cell digestion and culture and the like. Primary human tumor cells are cultured by a conditioned culture medium generated by fibroblasts irradiated by X-rays (X) and a cobalt-60 radioactive source (60Co), and culture conditions of key features of parent tumors and a modeling process can be most effectively reserved by screening and optimizing the culture conditions. And whether the PDC retains the key characteristics of the parent tumor or not is inspected on the aspects of the cell molecular level, the cell phenotype, the animal intracranial tumor model and the like.

The invention discloses a method for generating a magnetic resonance gadolinium contrast enhancement image based on contrast learning and an SDACL model, and further comprises the step of carrying out patch-based multi-layer contrast learning on the SDACL model and adjusting a designed loss function, the SDACL model comprises a domain X representing a multi-mode MRI channel superposition image, a domain Y representing a T1CE image, generators G and F and a discriminator network; according to the method, T1, T2 and Flair magnetic resonance plain scanning sequence images of a glioma patient are utilized to generate a T1 weighted enhanced sequence image, an attention dilation generator is adopted, a receptive field is expanded by utilizing an expansion residual block, and local features and global dependency of an input image are combined by means of a convolutional attention module (CBAM). According to the method, the feature representation and context learning of the multi-sequence MRI are enhanced, a comprehensive loss function is further designed, the comprehensive loss function comprises patch-level contrast loss and structural similarity loss, noise can be effectively restrained, and the structural consistency of a generated image and a real image is guaranteed.

The invention belongs to the technical field of medical image processing, and particularly relates to a glioma segmentation method based on a multimodal fusion network guided by anatomical symmetry, which comprises the following steps of: jointly inputting an FLAIR image, a T2 image, a T1 image and a T1c image of the same glioma into a trained image segmentation model, and outputting a predicted segmentation image by the trained image segmentation model, the prediction segmentation image is a glioma MRI image with three segmentation areas obtained through prediction, and the three segmentation areas are an edema area, an enhanced tumor area and a necrosis area respectively; the image segmentation model comprises an encoder, a jump connection part and a decoder; the encoder comprises an ASG module, the jump connection part comprises an IMP module, and the decoder comprises a CMF module. Through a three-module cooperation mechanism, the performance of tumor localization, cross-modal fusion, subregion segmentation and the like is improved, and a reliable image basis is provided for glioma operation plan formulation, prognosis evaluation and personalized treatment decision.

A boron carrying agent, a preparation method therefor, and a pharmaceutical formulation. The boron carrying agent contains compound 1, N-4-carboxyphenylboronic acid amide-threonine-phenylalanine-phenylalanine-tyrosine-glycine-glycine-serine-arginine-glycine-lysine-arginine-aspartic acid-aspartic acid-phenylalanine-lysine-threonine-glutamic acid-glutamic acid-tyrosine-cysteine, having a molecular formula of C114H158BN30O35S1 and a molecular weight of 2552.4, and further contains compound 2, N-4-carboxyphenylboronic acid amide-arginine-lysine-lysine-lysine-arginine-arginine-glutamine-arginine-arginine-arginine, and / or compound 3, N-4-carboxyphenylboronic acid amide-methionine-alanine-serine-methionine-threonine-glycine-glycine-glutamine-glutamine-methionine-glycine. Compounds 1-3 can serve as a targeted medicament for boron neutron capture therapy used for treating a cerebral glioma and a head and neck tumor.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

Preparation for an siRNA and drug co-delivery system for efficiently targeting glioma initiating cells, and a use; D VAP targeting peptide modification is performed on exosomes by utilizing a click chemistry method, siRNA and mitoxantrone are loaded into the exosomes, and construction is performed to obtain a target-modified drug carrier exosome DVAP-Exo / siRNA / MIT. The target-modified exosome co-carries chemotherapeutic mitoxantrone, which has a strong killing effect on glioma initiating cells and can trigger immunogenic cell death, and a small interfering nucleic acid (siNotch 1), which is capable of reducing glioma initiating cell stemness; targeted tracking and killing of residual glioma initiating cells and tumor cells are achieved, and a new avenue is provided for glioblastoma treatment.

The invention provides a nano-drug for treating glioma as well as a preparation method and application of the nano-drug, and particularly, the nano-drug comprises a nano-carrier and a carrier drug. The nano-drug can interact with a receptor on a brain endothelial cell, enters a brain tumor microenvironment through an endocytosis way, promotes antigen presenting cell maturation, activates T cell anti-tumor immune response, and effectively inhibits tumor growth.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The invention discloses a limonin compound and application thereof in preparation of a medicine for preventing and / or treating cancers. The structure of the limonin compound is shown as a formula I or II. The cancer is at least one of breast cancer, liver cancer, gastric cancer, esophageal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, prostatic cancer, nasopharynx cancer, cervical cancer, ovarian cancer, kidney cancer and skin cancer. According to the invention, activity screening is carried out on various natural product extracts, it is found for the first time that limonin compounds with structural formulas I and II have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. Related results also show that the compound provided by the invention can inhibit migration and invasion ability of breast cancer cells, promote cell apoptosis and retard a cell cycle. The limonin compound applied in the invention is derived from mallotus oblongifolius, the source is wide, and the production cost is low.

The invention discloses a glioma radiotherapy postoperative risk assessment method based on a magnetic resonance image, particularly relates to the field of glioma radiotherapy patient health risk assessment, and is used for solving the problem that an existing assessment mode depends on manual interpretation and is difficult to predict bad clinical outcomes in advance. The method comprises the following steps: performing clinical data gridding reconstruction on a corticoid use cycle of a patient and tumor molecular typing, and combining morphological characteristics of an edema region in a magnetic resonance image to generate time-aligned clinical comprehensive characteristic vectors; mining a frequent association item set between the comprehensive feature vector and the pathological process to construct a mapping relation model; establishing a probability graph reasoning model of the bad outcome based on the pathological process vector sequence and the probability weight; and integrating the two types of models to form a causal reasoning network, and inputting a target patient feature vector to calculate an accumulated risk value of reaching a bad outcome. According to the method, an interpretable individual risk assessment result can be output, and a basis is provided for postoperative follow-up visit and intervention.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention particularly relates to application of phellinus igniarius exosomes in glioma treatment, an extraction method and a composition. The phellinus igniarius exosome is provided by taking phellinus igniarius as a raw material through operations such as soaking, crushing and centrifuging, and the phellinus igniarius exosome is verified to have anti-glioma activity in vitro. Based on the research result, the invention provides a new application of the phellinus igniarius-derived plant exosome in glioma treatment, and provides a potential active component with low cost for glioma drug development.

The invention belongs to the technical field of glioma image recognition, and discloses a glioma area rapid recognition method and system based on a medical image. The method comprises the following steps: acquiring a multi-modal image sequence of a brain to be detected; performing weighted fusion on the multi-modal image sequence to generate a fused image; performing gray asymmetry analysis on the fused image, and identifying an asymmetry salient region of the fused image; performing texture difference analysis on the fused image, and extracting a high-difference region of the fused image; performing spatial intersection operation on the asymmetric salient region and the high-difference region, and taking a spatial intersection operation result as a glioma suspicious region; and carrying out dynamic region growth segmentation on the glioma suspicious region, and rapidly outputting a glioma region boundary. According to the method, dual feature screening of gray and texture is combined with dynamic region growth segmentation, the tumor infiltration boundary is accurately captured, the positioning precision is improved, and the false positive rate of recognition is reduced.

The invention discloses application of a CXCL14 combined immune checkpoint inhibitor in treatment of spinal glioma. The immune checkpoint inhibitor is selected from a PD-1 inhibitor or a combination of the PD-1 inhibitor and a CTLA4 inhibitor. In-vivo and in-vitro experiments prove that the CXCL14 combined with the PD-1 inhibitor, the CXCL14 combined with the PD-1 inhibitor and the CTLA4 inhibitor can be used for remarkably inhibiting the growth of mutant spinal glioma and have a remarkable synergistic effect. The invention provides a new strategy for treatment of spinal glioma, and is widely applied clinically.

The invention discloses a glioma radiotherapy response prediction model construction method, a medium and a product, and relates to the technical field of medical instruments. According to the method, feature extraction and screening are carried out on the magnetic resonance images based on the radiomics technology, the sample data set is constructed, then the linear regression model is trained by using the sample data set, the trained linear regression model is obtained to serve as the glioma radiotherapy response prediction model, and glioma radiotherapy response prediction is realized.

The invention relates to the technical field of nano medicine, in particular to iron gambogic acid adriamycin nano particles, a preparation method and application. Gambogic acid, doxorubicin hydrochloride and an iron-containing compound are matched, carbonyl oxygen and hydroxyl in the gambogic acid and Fe < 3 + > form coordinate bonds, carbonyl and amino in the doxorubicin hydrochloride and a conjugated system in a benzene ring are combined with Fe < 3 + > through covalent bonds and pi-pi accumulation, a core-shell structure is formed, and the iron gambogic acid doxorubicin nano-particles are obtained. The particle size of the iron gambogic acid adriamycin nano-particles ranges from 2 nm to 10 nm. The iron gambogic acid adriamycin nano-particles have excellent multi-enzyme activity, autophagy amplification is effectively achieved, traditional chemotherapy drug resistance caused by autophagy is overcome, and the glioma chemotherapy effect is improved.

The invention discloses application of tryptophan derivatives of parthenolide in preparation of glioma drugs, and belongs to the technical field of drugs. Aiming at the problems of poor water solubility, unstable metabolism and the like of the existing parthenolide and derivatives thereof, the invention provides a tryptophan derivative PDTry-TZ with remarkable anti-tumor activity. The IC50 value of the derivative is as low as 3.352 M / ml, tumor cell growth can be remarkably inhibited, and the derivative is prepared through a specific synthesis method. The tryptophan derivative PDTry-TZ of parthenolide provides a new drug candidate for glioma treatment, and is expected to improve the treatment effect, reduce side effects and improve the life quality of patients. In conclusion, the invention not only solves the existing technical problems, but also brings a new breakthrough to the field of glioma treatment, and has important application value.

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

In one aspect, described herein is a method of treating a relapsed or refractory pediatric low-grade glioma (pLGG) in a subject in need thereof, comprising administering to the subject tovorafenib or a salt thereof, wherein the subject is 6 months of age or older. In some embodiments, the pediatric low-grade glioma (pLGG) harbors a BRAF fusion or rearrangement, or BRAF V600 mutation. In some embodiments, the method comprises administering a starting dose, a reduced dose, and optionally a further reduced dose.